Hayman, Thomas J. http://orcid.org/0000-0001-7046-2276
Baro, Marta
MacNeil, Tyler
Phoomak, Chatchai http://orcid.org/0000-0002-3808-8816
Aung, Thazin Nwe
Cui, Wei
Leach, Kevin
Iyer, Radhakrishnan
Challa, Sreerupa
Sandoval-Schaefer, Teresa
Burtness, Barbara A.
Rimm, David L. http://orcid.org/0000-0001-5820-4397
Contessa, Joseph N. http://orcid.org/0000-0001-9408-1865
Funding for this research was provided by:
Yale SPORE in Lung Cancer and Yale Cancer Center
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (P50 DE030707)
Yale Cancer Center Pilot and Discovery Grants
Article History
Received: 13 March 2020
Accepted: 17 March 2021
First Online: 19 April 2021
Competing interests
: J.N.C. has a research agreement with Spring Bank Pharmaceuticals. D.L.R. has served as a consultant, advisor, or served on a Scientific Advisory Board for Amgen, Astra Zeneca, Agendia, Biocept, BMS, Cell Signaling Technology, Cepheid, Daiichi Sankyo, GSK, Merck, NanoString, Perkin Elmer, PAIGE, Sanofi, and Ultivue. He has received research funding from Astra Zeneca, Cepheid, Nanostring, Navigate/Novartis, NextCure, Lilly, Ultivue, and Perkin Elmer. B.A.B. received an honorarium from Aduro. K.L., R.I., and S.C. were employed by Spring Bank Pharmaceuticals/F-STAR. All remaining authors declare no competing interests.